SkinBioTherapeutics Plc
SBTX.L · LSE
6/30/2025 | 6/30/2024 | 6/30/2023 | 6/30/2022 | |
|---|---|---|---|---|
| Market Cap | – | £16,766 | £20,589 | £31,748 |
| - Cash | £4,779 | £801 | £1,312 | £1,805 |
| + Debt | £881 | £819 | £101 | £128 |
| Enterprise Value | – | £16,784 | £19,378 | £30,071 |
| Revenue | £4,638 | £1,209 | £132 | £75 |
| % Growth | 283.6% | 815.5% | 76.6% | – |
| Gross Profit | £2,706 | £683 | £85 | £45 |
| % Margin | 58.3% | 56.5% | 64.5% | 60.6% |
| EBITDA | -£197 | -£2,722 | -£2,955 | -£2,952 |
| % Margin | -4.2% | -225.1% | -2,237.8% | -3,949.1% |
| Net Income | -£696 | -£2,876 | -£2,835 | -£2,793 |
| % Margin | -15% | -237.9% | -2,146.9% | -3,735.4% |
| EPS Diluted | -0.003 | -0.015 | -0.017 | -0.018 |
| % Growth | 79.9% | 10.5% | 3.4% | – |
| Operating Cash Flow | -£1,298 | -£2,726 | -£2,645 | -£2,673 |
| Capital Expenditures | -£6 | -£198 | -£165 | -£97 |
| Free Cash Flow | -£1,304 | -£2,924 | -£2,810 | -£2,770 |